Britain might not have produced any large new biotech enterprises like America’s Amgen, Biogen or Gilead, but there are notable successes for which the country should be proud. It is against these which entrepreneurs and managers of today’s biotech companies should set their ambitions and measure their success.
It’s all too easy to look to failures – of markets, Government interventions and companies - indeed this was the theme in the book Science, the State and the City: Britain's Struggle to Succeed in Biotechnology by Geoffrey Owen and Michael M. Hopkins published last year. Based on a rich analysis of the UK’s last 40 years of investment in biotech, they concluded that the UK has not succeeded in creating Bellweathers – as measured in terms of UK stock market valuations of therapeutic biotechs.
20 years ago Instinctif Partner’s Sue Charles introduced a now famous sheep to the world
In February 1997, via a publication in Nature, scientists in Scotland announced the birth of the world's first successfully cloned mammal, and it was Instinctif Partners Managing Partner Sue Charles, who led the PR effort to introduce ‘Dolly the sheep’ to the world.
Instinctif Partners has been awarded silver in the large consultancy category by PR Week for Best Places to Work
These awards recognise those UK-based consultancies and in-house comms departments that go the extra mile to offer a superb working environment and progressive practices in the workplace, whether it's around training, mentoring, pay, maternity and paternity issues, or a host of other areas.
The International Communications Consultancy Organisation (ICCO) has awarded the accolade of Regional Independent Consultancy of the Year (EMEA) to Instinctif Partners at an awards ceremony in London on Thursday 1 December 2016.
14-20 November 2016 - World Antibiotic Awareness Week aims to increase awareness of global antibiotic resistance and to encourage initiatives to avoid the further emergence and spread of antibiotic resistance.
European Antibiotic Awareness Day comes at the end of the week, on 18 November and is an annual European public health initiative to raise awareness about the threat to public health of antibiotic resistance and the importance of prudent antibiotic use.
In a continued run of award success, Instinctif Partners has been named UK PR Consultancy of the Year at the 2016 Corporate and Financial Awards. Its work for its clients was also recognised in five categories. The Corporate and Financial Awards recognise and celebrate excellence in all aspects of business communication.
For over 10 years Instinctif Partners has supported Jeans for Genes Day. On Friday 23 September we will once again be leaving our suits at home and wearing jeans to help to raise money for this great cause – helping to fund the vital care and support services that transform the lives of 1 in 25 children also inherit a genetic disorder that makes their life very difficult.
Instinctif Partners was delighted to be on the Biotech and Money Advisory Board and 2016 Awards executive judging panel in June - looking forward to the Awards Gala Dinner on the 6 September at the Gibson Hall, London.
Good luck to all the finalists, including our clients Abcam, Abzena, Auspherix, Autifony, Clinigen, Immunocore, Novabiotics and Puridify.
On 23 June the UK voted in a referendum to leave the EU. As this process and its ramifications unfold over the coming months and years, Instinctif Partners is helping its clients to steer their businesses successfully through this period of change and uncertainty.
On Tuesday, 21 June 2016 Instinctif Partners hosted the Biotech and the City Summer event, the main mid-year networking event for Biotech and Money community members. The evening was a great success and served as an informal forum for senior executives to come together, network and enjoy a relaxed evening of great networking with their peers.
London: On Thursday, 12 May 2016, Instinctif Partners, the business communications consultancy, sponsored and hosted the 2016 UK BioIndustry Association (BIA) Annual Lecture – ‘An evening with Dr Clive Dix’. The BIA is the trade association for innovative enterprises involved in UK bioscience.
Our core strength is supporting organisations at the interface of innovation and wealth creation – to help them communicate their innovative science and new medical devices and treatments. With any new technologies, communications is a critical tool to ensure the innovations are adopted by customers and accepted and appreciated by the wider publics and society. In a sector that burns billions in cash ahead of any new product launch, it’s also vital that investors are excited by the potential and can see the value in new innovations. It’s truly an honour to be able to work with so many entrepreneurs and game-changing companies, in areas such as stem cells, gene therapy, immune-oncology, personalised medicine, the microbiome and genetic-based diagnostics. Whilst the individual brands of many of our early-stage clients are not widely known, they are changing the health outlook for all of us, and it’s exciting to be part of it. Read more
One Nucleus BioWednesday event sponsored and hosted by Instinctif Partners, co-sponsored by Coulter Partners
Wednesday 7 October 2015
65 Gresham Street, EC2V 7NQ (near St Paul’s)
5pm (registration) – 9pm (close)
For a chance to put key life science media on the spot join us for a 60-minute Q&A session, which will bring a great opportunity for those who engage with the media (CEOs, CFOs etc) to quiz leading journalists on new trends and best practice, and for media experts to discuss how best to work with them.
Without a change of behavior, antibiotic resistance is an increasingly serious threat to global public health, posing a ‘catastrophic threat’ that could return us to an era where deaths due to common infections are rife. Be aware, be educated, be responsible and support actions to ensure that future generations can enjoy modern medical advances made possible through keeping bacterial infections at bay through the effective use of antibiotics says Instinctif Partners.
Instinctif Partners has built an impressive Public Policy offering with notable expertise in pharma and medtech across its teams in the UK (London) and the EU (Brussels). With the acquisition of Brand Associates, this experience is extended to Germany (Berlin). Brand’s clients in the Life Sciences sector include Boehringer Ingelheim, GlaxoSmithKline, Johnson & Johnson, Lilly Deutschland and PhRMA. Read more
College Group (including leading brands College Hill, The College, College Public Policy, Policy Action, Green Issues Communique, Stockheim Media and Instinctif) is rebranding and unifying its business operations under one single brand – Instinctif Partners.
We have also moved to our new London headquarters at 65 Gresham Street, London, EC2V 7NQ.
Since the start of 2013, the market for IPOs on NASDAQ has been very buoyant. With little activity over the past few years, it has been a welcome change by many biotech companies that have taken advantage of the opening of the funding window to list on NASDAQ including our client Prosensa Holding N.V.
BIO International Congress, April 22-25 2013, Chicago, USA
In its twentieth year, BIO is the biggest event in the life science sector. Senior Account Director Stefanie Bacher and Junior Account Director Dr Anastasios Koutsos represented College Hill at the conference, reporting a whirlwind experience, which could be summarized under the motto “think big”. An exhibit hall floor of 2,670,000 sq ft alone, the size of four football fields, 15,000 attendees from all over the world and the amount of energy was impressive to say the least. Recapping information from 125+breakout sessions, 800+ speeches, 6 super sessions and a couple of keynotes seems like a mission impossible. After digesting the event, here are their ‘top 10’ highlights...
College Hill Life Sciences congratulates all the nominees shortlisted for the European Mediscience Awards 2013, especially those individuals and companies in the category, Commentator of the Year, of which College Hill is the sponsor.
Of College Hill Life Sciences own clients, congratulations go to Clinigen Group (Transaction of the year, Emerging Company), Imperial Innovations (Most Significant Contribution), and Oxford Gene Technology (Emerging Star).
In March College Hill Life Sciences’ ASX-listed client Mesoblast closed AU$170 million (US$176 million) in a private placing with institutional investors. Based on BioWorld’s Insight report issued early March, this is the largest Life Sciences private financing of a public company globally of 2013, just pipping the amounts raised by US-based Ironwood Pharmaceuticals (NASDAQ) and OPKO Health Inc. (NYSE) in January. AIM-listed client, e-Therapeutics, which raised £40 million (US$63m) from an issue of new shares in February, would place it as the fifth largest financing according to figures in the BioWorld report.